Get started
Author

Alessio Bevilacqua

Observed name: A. Bevilacqua
ORCID: 0000-0001-7009-4362
Observed ORCID: 0000-0001-7009-4362
OpenAlex ID: A5049298421
Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity
2021 · Yugang Guo, Yu-Qing Xie, et al. · Nature Immunology · 464
Reductive carboxylation epigenetically instructs T cell differentiation
2023 · Alison Jaccard, Tania Wyss, et al. · Nature · 114
Regulatory circuits of mitophagy restrict distinct modes of cell death during memory CD8 + T cell formation
2023 · Fabien Franco, Alessio Bevilacqua, et al. · Science Immunology · 52
Metabolic dynamics instruct CD8 + T‐cell differentiation and functions
2022 · Alessio Bevilacqua, Zhiyu Li, et al. · European Journal of Immunology · 41
PDF
PPARβ/δ-orchestrated metabolic reprogramming supports the formation and maintenance of memory CD8 + T cells
2024 · Alessio Bevilacqua, Fabien Franco, et al. · Science Immunology · 35
Tumor-instructed glutamine synthesis in cancer-associated fibroblasts promotes pro-tumor macrophages
2025 · Xiaoyun Li, Sofie Hedlund Møller, et al. · The Journal of Experimental Medicine · 30
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance
2026 · Xin Li, Cynthia Lebeaupin, et al. · Nature · 16
Metabolic reprogramming in inflammaging and aging in T cells
2023 · Alessio Bevilacqua, Ping-Chih Ho, et al. · Life Metabolism · 14
PDF
The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial
2026 · Anna Maria Di Giacomo, Matteo Simonelli, et al. · Nature Communications · 5
PDF
The PI3Kδ inhibitor roginolisib ( IOA ‐244) preserves T‐cell function and activity
2026 · Elise Solli, Alessio Bevilacqua, et al. · Molecular Oncology · 4
Androgen effects cause sex-biased impairment of CD8 + T cell antitumor activity
2022 · Alessio Bevilacqua, Ping-Chih Ho · Science Immunology · 1
1181 Roginolisib plus dostarlimab with or without docetaxel reverts immune suppression and shows clinical activity in immunotherapy-resistant non-small cell lung cancer (NSCLC)
2026 · Reinier Wener, Aitor Azkàrate Martínez, et al. · Journal for ImmunoTherapy of Cancer
PDF
POSTER: MPN-545: The Selective PI3KδInhibitor Roginolisib Synergizes With JAK Inhibitors in Progenitor Cells From Naïve and JAK Inhibitor–Refractory/Resistant Patients With Myelofibrosis
2026 · Manjola Balliu, Valentina Boldrini, et al. · Clinical Lymphoma Myeloma & Leukemia
MPN-545: The Selective PI3KδInhibitor Roginolisib Synergizes With JAK Inhibitors in Progenitor Cells From Naïve and JAK Inhibitor–Refractory/Resistant Patients With Myelofibrosis
2026 · Manjola Balliu, Valentina Boldrini, et al. · Clinical Lymphoma Myeloma & Leukemia
453P Proteomic evidence of on-target activity of cambritaxestat (IOA-289) in patients with metastatic pancreatic ductal adenocarcinoma
2026 · D. Melisi, G. Di Conza, et al. · Annals of Oncology
PDF
200P Patient tumor profiling supports the antitumor activity of the autotaxin inhibitor cambritaxestat (IOA-289) as monotherapy and in combination with standard of care in hepatocellular carcinoma and cholangiocarcinoma
2026 · A. Bevilacqua, M.A. Deken, et al. · Annals of Oncology
PDF
Abstract 5763: Roginolisib stabilizes inactive PI3Kdelta to deliver specific target blockade with reduced immune toxicity
2026 · Giusy Di Conza, Oscar Vadas, et al. · Cancer Research
Author response for "The PI3Kδ inhibitor roginolisib (IOA-244) preserves T cell function and activity"
2025 · Elise Solli, Alessio Bevilacqua, et al. · Publons reviews and discussion
Abstract 2055: Molecular profiling of the PI3Kδ inhibitor roginolisib in metastatic uveal melanoma and its correlation with clinical outcomes
2025 · Alessio Bevilacqua, Tan Ziyang, et al. · Cancer Research
Works count: 19
Citation count: 776
H-index: 8
I10-index: 8
Year
Topic
Type